CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¼Û¿µ½Å
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °©»ó¼±Áúȯ/´ç´¢º´/±âŸ ³»ºÐºñ ´ë»çÁúȯ
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
151 (±¹¿Ü)SCI Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
150 (±¹¿Ü)SCI Prolonged Use of Carnitine-Orotate Complex (Godex¢ç) Is Associated with Improved Mortality: A Nationwide Cohort Study
149 (±¹¿Ü)SCI FGM-Based Remote Intervention for Adults With Type 1 Diabetes: The FRIEND Randomized Clinical Trial
148 (±¹¿Ü)SCI Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
147 (±¹¿Ü)SCI Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: A randomized controlled trial
146 (±¹¿Ü)SCI The Risk of Neurodegenerative Diseases in Patients With Acromegaly: A Cohort Study
145 (±¹³»)KCI Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
144 (±¹¿Ü)SCIE Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
143 (±¹¿Ü)SCI Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-calculate Marker for All-cause and Cardiovascular Mortality
142 (±¹³»)SCIE Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729